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Abstract: Millions of blood products are transfused every year; many lives are thus 
directly concerned by transfusion. The three main labile blood products used in transfusion 
are erythrocyte concentrates, platelet concentrates and fresh frozen plasma. Each of these 
products has to be stored according to its particular components. However, during storage, 
modifications or degradation of those components may occur, and are known as storage 
lesions. Thus, biomarker discovery of in vivo blood aging as well as in vitro labile blood 
products storage lesions is of high interest for the transfusion medicine community.  
Pre-analytical issues are of major importance in analyzing the various blood products 
during storage conditions as well as according to various protocols that are currently used 
in blood banks for their preparations. This paper will review key elements that have to be 
taken into account in the context of proteomic-based biomarker discovery applied to blood 
banking. 
Keywords: labile blood products; aging and storage lesions; biomarkers; pre-analytics; 
proteomics 
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1. Blood Components Preparation and Storage 
Whole blood transfusion is nowadays realized in very limited cases. Indeed, transfusion therapy 
now mainly relies on administration of the blood component really needed by the patients. The three 
main labile blood components used in transfusion therapy are erythrocyte concentrates (ECs), platelet 
concentrates (PCs) and fresh frozen plasma (FFP). These products can be obtained either by processing 
a whole blood donation (450–500 mL), which is the most common and simplest technique, or by 
apheresis where only the needed component is taken from the donor, the remainder been returned to 
the donor [1]. This last technique is more expensive and requires a more consistent facility.  
The standard procedure of blood products preparation from whole blood donation is as follows: 
once collected in plastic bags containing citrate phosphate dextrose (CPD) anticoagulant, whole blood 
is centrifuged in order to separate blood cells according to their size and density. Red blood cells 
(RBCs) settle, while plasma remains on the top. White blood cells and platelets (PLTs) form a “buffy 
coat” layer at the interface. Finally, the three components are distributed among the sterile  
inter-connected blood bags by applying a semi-automated pressure to the centrifuged bag containing 
the original whole blood donation.  
In order to prevent various post-transfusion reactions and anti-HLA allo-immunisation, whole blood 
donation is impoverished in white cells by filtration (erythrocyte plasticity allows to pass through the 
membranes, contrary to white cells that are retained). Indeed, as leukocytes could be pathogens 
containing cells, blood products are systematically leukodepleted. A retrospective study has 
demonstrated that the rates of febrile nonhemolytic transfusion reactions (FNHTRs) are decreased by a 
factor of 1.7 and 4.1 after RBCs and PCs transfusion respectively, since the establishment of 
systematic prestorage leukodepletion [2]. 
Each component obtained from whole blood has optimal storage conditions, which permits to 
preserve its specific activities and functions. The temperature is a particularly important storage 
parameter regarding the viability and the quality of products intended for transfusion. Supplemented 
with an additive solution, generally a saline-adenine-glucose-mannitol (SAGM) solution, RBCs can be 
stored for up to 42 days from +2 °C to +6 °C, in order to preserve the functionalities of erythrocytes. 
On the contrary, PLT are stored from +20 °C to +24 °C up to 5 days, with sufficient agitation to permit 
a good oxygenation and to prevent platelet aggregation. Storage at room temperature promotes 
bacterial proliferation, and thus increases the risk of transmitted bacteria. The dilemma is that if 
platelets are transfused after refrigeration at 4 °C, they are rapidly cleared from the recipient 
circulation [3]. Finally, as indicated by its name, FFP has to be frozen, for an optimal storage, at least 
at −25 °C, for up to 36 months. 
These limits depend on local legislation, and depend on the additive solutions used in erythrocyte 
and platelet concentrates. These three labile blood products can be further differentially processed 
depending on demand for particular biomedical needs (-irradiation, washing and so on). 
2. Blood Products Storage Lesions 
Even under current optimal storage conditions, modifications and/or degradation of blood 
components occur in blood bags. These alterations, known as “storage lesions”, affect lifespan and 
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quality of the stored blood products [4]. Even though it is unknown if storage lesions are consequences 
of the natural aging of blood components, these lesions are well described in the literature.  
2.1. Erythrocyte Concentrates Storage Lesions 
Red blood cells storage lesions can be classified in different categories, depending on their physical 
or chemical properties [5,6]. 
First, some biochemical changes related to the energy metabolism occur. It appears that components 
such as ATP, which is necessary for multiple cellular processes, and 2,3-DPG, which plays an 
important role in oxygen release, rapidly decrease during the storage. ATP level is considerably 
diminished after 5 weeks of storage while the 2,3-DPG is almost null after 2 weeks of storage [7]. The 
low concentration of 2,3-DPG increases hemoglobin affinity for oxygen, which cannot be delivered 
anymore. However, these levels are rapidly recovered in blood circulation after transfusion of the 
erythrocyte concentrate. It is also known that intracellular sodium and potassium levels are altered 
through storage. Indeed, Na
+
/K
+
 pumps are inactive at 4 °C, thus allowing high sodium influx and 
potassium loss [7]. 
Then, RBCs storage induces biomechanical changes. The erythrocytes rheological properties, such 
as shape, deformability, aggregability, and intracellular viscosity are altered during storage [8]. All 
these changes impact the red blood cells ability to pass through microvessels, thus altering their 
oxygenation capacities. This is very problematic in blood banking, and neither SAGM nor  
phosphate-adenine-glucose-guanosin-saline-mannitol (PAGGSM), the two mostly used additive 
solutions, are described to prevent these storage lesions [9]. 
Finally, modifications also take place at the protein level. Indeed, erythrocytes are subjected to 
oxidative lesions, which result in protein oxidative modifications [10,11], hemichrome formation and 
Band 3 clustering. Storage-induced protein degradation appears to be greatly reduced when oxygen is 
removed and blood is stored under helium [12]. Antonelou et al. have shown that erythrocyte proteins 
are less oxidized when RBCs are stored in CPD-SAGM compared to storage in CPD-Adenine [13]. 
Mechanisms of oxidative damage along the development of storage lesions and investigations of the 
effect of blood anaerobic storage conditions have been recently described by Yoshida and 
Shevkoplyas [14]. 
Some aspects of RBC aging occurring in vivo and in vitro during storage are similar. For example, 
the increase of intracellular calcium level induces microvesiculation and externalization of  
negatively-charged membrane phospholipids (phosphatidylserine) [15]. RBCs clearance from blood 
circulation is thought to be immunologically mediated. Several studies have led to the so-called Band 3 
clustering model [16,17]. Oxidized hemoglobin compounds aggregate to form hemichromes that 
accumulate at the inner side of erythrocytes membrane, covalently bound with cytoskeletal proteins 
such as spectrin, thus inducing alterations of RBC deformability. Interaction of hemichromes with 
cytoplasmic domains of Band 3 leads to Band 3 clustering. This conformational change of the major 
erythrocyte membrane protein is recognized by naturally occurring anti-Band 3 auto-antibodies 
(nAbs) [18–20]. Paleari et al. have demonstrated that the number of these RBC-bound IgGs increases 
in old population enriched fractions (through Percoll density fractionation), as well as in some selected 
clinical cases of patients with altered RBC survival [21]. These observations lead to the conclusion that 
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RBC-bound IgG is a biomarker of aging. Hemicromes, Band 3 dimerization and erythrocyte 
recognition by nAbs are thus additional RBCs aging markers that can be investigated. 
2.2. Platelet Concentrates Storage Lesions 
Platelet Storage Lesions (PSL) consist in morphological changes, platelet activation, platelet 
proteolysis and platelet surface receptor expression [22,23]. Changes of platelet membrane 
glycoproteins are also reported in numerous papers [24–26]. 
The normal platelet discoid shape (also referred as resting shape) is found to be lost after 5 to 7 days 
of storage at 22 °C. At this storage time, mainly spherical or fragmented platelets remain. Granule 
release and platelet activation occur during PLT storage, as indicated by the accumulation of  
β-thromboglobulin and platelet factor 4 in the storage medium, and the increase in surface levels of  
P-selectin (CD62P), respectively.  
In vitro, loss of aggregation functionality is also observed. There is a significantly storage-
dependant decrease of platelet aggregation response to a number of agonists used alone, such as 
adenosine diphosphate (ADP), epinephrine, collagen and arachidonic acid [27]. However, these 
aggregation agonists seem to have a synergistic action since pairs of them have been shown to restore 
platelet aggregation, even after five days of storage [27]. Shapira et al. have also shown that platelet 
prothrombinase activity and membrane phosphatidylserine exposure are enhanced during PCs blood 
banking storage [28]. 
As blood components natural aging and storage lesions can directly affect cells, and also have 
implications at the protein level, the analysis of biomarkers of such phenomenon must be ruled out by 
important pre-analytical considerations. 
3. Analysis of Blood Products Aging and Storage Lesions Biomarkers: Pre-Analytical Issues 
3.1. Importance of Pre-Analytics in Biomarker Discovery Field 
In order to be used in medicine, a biomarker has to be both sensitive and specific. Indeed, a 
biomarker of a given physiological state must allow the identification of this state (sensitivity) and 
must not be relevant to another physiological state (specificity). However, only few of them meet all 
criteria making an efficient biomarker suitable for clinical uses. 
In the field of biomarker discovery, an important issue is to control sample preparation steps and 
pre-analytical factors. Specificities of a biomarker have to be the same everywhere following the same 
protocol. For that reason, the standardization of procedure controlling pre-analytical steps (sampling, 
conservation and preparation) has to be elaborated. 
As discussed before, the three main labile products are differentially processed and stored in order 
to maintain their viability and quality for transfusion therapy. Standards are published by competent 
authorities in each country. However, even if the procedure is similar, there are still minor changes 
applied worldwide. Indeed, blood labile products have to meet definite standards, whatever the way of 
production and the material used. For example, quality of platelet concentrates varies according to the 
platelet additive solution used [29]. 
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3.2. Proteomics in Blood Transfusion 
3.2.1. Proteomic Tools for Biomarker Discovery 
Proteomics has been largely used in the field of biomarker discovery [30,31] as well as in 
transfusion medicine [32,33] since proteins are the effective form of genes, and are thus more able to 
inform about the physiological state. Indeed, contrary to the genome, the proteome composition 
fluctuates during time, changes among cell population and is physiological state-dependent.  
Clinical proteomics is a major asset for diagnosis, prognosis or evolutionary biomarkers. Varieties 
of improved proteomic technologies allow separation, identification and quantification of proteins, 
here potential biomarkers. Gel-based technologies (two-dimensional gel electrophoresis, 2DE, and 
two-dimensional differential gel electrophoresis, 2D-DIGE), as well as chromatographic techniques 
(e.g., reverse phase liquid chromatography, RPLC, and strong cation exchange liquid chromatography, 
SCX-LC) have been developed in order to fractionate proteins or peptides from complex samples. 
Then, proteins can be analyzed by mass spectrometry (MS) consisting in the ionization of proteins or 
peptides in order to identify them according to their mass-to-charge ratio (m/z). The two commonly 
used sources of ionization are matrix-assisted laser desorption/ionization (MALDI) and electrospray 
ionization (ESI). MALDI source is preferentially combined with time-of-flight (TOF) analyzer, 
whereas the ESI source is coupled with quadrupole (Q), ion trap (IT), fourier transform ion cyclotron 
resonance (FTICR), Orbitrap or combinations of these analyzers. Peptide mass fingerprinting (PMF) or 
de novo sequencing by tandem mass spectrometry (MS/MS or MS²), combined with powerful 
bioinformatic tools allow protein identification by database interrogation. Protein quantitation [34,35] 
can be achieved thanks to diverse treatments before or after the sampling step [36] (metabolic stable 
isotope labeling of amino acids in cell culture, SILAC [37], and chemical addition of isotope-coded 
affinity tags, ICAT [38], or isobaric tags for relative and absolute quantitation, iTRAQ [39]), by 
spiking samples before MS analysis with known amount of an isotopically labeled analyte (absolute 
quantitation of proteins, AQUA [40]) and even by recently developed label-free methods, based on MS 
or chromatography data-processing (spectral counting [41] or total ion current, TIC, integration [42]). 
Surface enhanced lazer desorption/ionization time-of-flight (SELDI-TOF), also known as 
ProteinChip Array technology, is widely used in biomarker discovery [43,44]. A solid-phase 
chromatographic surface allows sample decomplexification according to chemical or biochemical 
properties. Users can design their own chromatographic surface to target specific protein population. 
Bound proteins are then ionized and analyzed as in classical MALDI-TOF MS analysis. However, 
SELDI-TOF MS analysis does not lead to protein identification, but only gives a mass list of proteins 
showing relative abundance differences between samples. Once targeted, these proteins have to be 
further purified then identified by standard mass spectrometry. Caputo et al. have developed such kind 
of methods for protein identification on ProteinChip surfaces, i.e., on-chip digestion and MS/MS 
sequencing by hybrid quadrupole-TOF [45]. 
Recent advances in all these proteomic techniques have improved reproducibility, but the problem 
of inter-laboratory reproducibility still subsists. To ensure this reproducibility, a control of the initial 
state of samples, with standardization of sample collection, storage and preparation conditions, is 
required. According to Lehmann et al. [46], the following pre-analytical steps have to be controlled: 
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the sampling procedure and the type of container, the temperature and the time before transport  
(if transport needed), the time between sample collection and sample processing, the process itself 
(centrifugation, aliquoting, type of secondary container), the storage (temperature and duration) and 
the pre-treatment just before proteomic analysis. 
The general complexity of a proteome, and particularly the huge dynamic range of protein 
abundance composing the blood proteome, makes necessary the fractionation of blood samples before 
proteomic analysis, by depletion or fractionation processes. Then, other sample preparation can be 
required depending on the type of analysis to be performed, and cannot be standardized to all 
biomarker discovery studies. 
3.2.2. Involvement of Proteomics in Blood Transfusion  
3.2.2.1. Erythrocyte Proteome Investigations 
Red blood cell is an abundant and easily obtained biological material having the particularity to be 
nucleus- and organelle-free. These characteristics have made of it a model of choice for membrane 
studies. Nowadays, thanks to development of proteomic tools and technologies, erythrocyte proteome 
begins to be well documented. Several major studies about RBC proteome have been published last 
decade, showing a great improvement in terms of number of identified proteins, in cytosolic as well as 
membrane extracts. 
In 2002, a first study combining one dimensional (sodium dodecyl sulphate polyacrylamide gel 
electrophoresis, SDS-PAGE) and 2D electrophoresis, allows identification of 84 unique proteins from 
ghost preparation by MALDI-TOF MS analysis. Classic SDS-PAGE reveals 25 proteins of high 
hydrophobicity and high molecular weight, undetectable with 2DE [47]. Two years later, the use of 
LC-MS has enabled Goodman and coworkers to identify 181 proteins after tryptic digestion of both 
cytoplasmic and membrane preparations [48]. Then, Pasini et al. have increased the number of 
identified proteins to 566 (314 membrane-associated proteins and 252 cytoplasmic proteins), 
combining high-accuracy and high-sensitivity protein identification technologies to analyze trypsin-
digested differentially extracted proteins from cytoplasmic and membrane fractions. They have tested 
different extraction methods leading to differences in number of identified proteins. This number also 
appeared to vary according to interrogated database [49]. In 2008, the peptide ligand library 
technology [50] made possible the exploration of red blood cell hidden proteome by reducing the 
erythrocyte dynamic protein concentration range, which permits Roux-Dalvai et al. to identify 1578 
soluble proteins by nano-LC-LTQ-Orbitrap MS/MS analysis [51]. A more recent study reveals 222 
identified proteins. Even though this number may appear low in comparison with other studies, the 
authors have set up an interesting hemoglobin depletion strategy, derived from the existing 
HemogloBind™ reagent [52]. In 2010, van Gestel et al. have explored RBC membrane proteome 
combining blue native protein separation (BN/SDS-PAGE), CyDyes labeling-based quantitation and 
LC-MS/MS identification [53]. This allowed them to identify 524 proteins, of which 155 are 
membrane proteins. The CyDyes labeling led to quantitation of a 40% decrease in spectrin levels in 
erythrocyte membrane fraction of a patient presenting RBC membrane disorder. This interesting 
approach thus seems to be applicable to biomarker discovery. Lately, efforts have been made in the 
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establishment of interactome and network maps, as reported by Goodman et al. [54] and updated by 
D’Alessandro et al. [55]. 
3.2.2.2. Platelet Proteomic Analyses 
Platelet quality was usually determined from measurable characteristics such as pH, platelet 
morphology and hypotonic shock responses. Protein analysis of platelets during storage was first 
achieved in the end of the 1980s by identifying variation in actin [56,57]. However, actin 
polymerization is linked to the method used in the preparation of PCs and it has been shown that this 
process is partially reversible after 1 day of storage [58], which is highlighting the implication of  
pre-analytics in biomarker discovery. Since the introduction of proteomics, new tools have been 
brought in order to characterize platelet storage lesions. As explained previously, lesions occur during 
storage of PCs and can alter several proteins and mechanisms. The proteome analysis of platelets 
during the period of storage may reveal different biomarkers, potentially important for improving 
platelet quality [59]. Proteomic analysis of platelets in vivo or during storage was achieved at the 
beginning of the last decade [59,60]. Using gel-based proteomics, different groups identified several 
hundreds to thousands of PLT proteins [61–63]. Based on peptidic-centric methods, 641 proteins were 
reported by Gevaert and coworkers, including hydrophobic membrane proteins [64]. Later, different 
studies have focused on changes during storage periods, typically between a 1-day and a 7-day storage. 
Thiele et al. have shown by DIGE and MS that 97% of cytosolic proteins do not change over a 9-day 
storage period [65]. However, in the 3 remaining percent, they highlighted that, for instance, spetin 2 
and gelsolin show changes in 2DE. They claimed that these proteins, affected during apoptosis, may be 
suitable markers for platelet alteration during storage. Using a similar approach but focusing on 
supernatant, it has been also shown that levels of proteins increase during storage, which may have 
some implications for transfusion recipients [66]. More recently, Devine and coworkers have used 
complementary proteomic methods (2DE, DIGE, iTRAQ and ICAT) to investigate protein changes 
between days 1 and 7 of PLT storage [67]. Hence, 503 proteins changed concentration was reported 
thus completing the PLT proteome.  
Beyond these analyses, the impact of such potentially biomarkers has to be integrated within 
molecular mechanisms leading to platelet storage. As explained by Schubert and Devine, biological 
interpretation of proteomic data has to be taken into account [59]. A comprehensive view of different 
mechanisms related to biomarkers may be required to understand how to improve platelet quality. 
Even though such an approach is far to be completed nowadays, changes in molecular mechanisms 
have been described. Schubert et al. have identified 12 proteins connected in one potential signaling 
pathway underlying storage lesion development [68]. They have shown that PI3-kinase-dependent 
Rap1 activation leads to integrin IIb3 activation and PLT degranulation. In addition, a PI3-kinase 
inhibitor incubated with PLT for 7 days plays a role in Rap1 activation and seems to improve PLT 
integrity and quality during storage. A global view, including protein-protein interactions [69], is one 
of the tools able to provide a wide picture of the storage lesions and mechanisms involved during such 
modifications. 
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All these studies have potential influence on the future of platelet quality and safety during storage, 
and of course, as it is explained within this review, pre-analytic considerations are inherent to  
these studies. 
3.3. Blood Proteomics Pre-Analytical Considerations 
All these blood-related studies can be impacted by pre-analytics. From sample collection to 
proteomic analysis, all manipulation steps are source of pre-analytical variation. The main  
pre-analytical considerations to take into account are resumed in Table 1. 
3.3.1. Sample Collection 
Blood donation conditions such as the donor position, the time of tourniquet application, and the 
needle bore size are important. In upright position, blood macromolecular component rates can be 
increased, due to a shift in body water from intravascular to interstitial compartment (macromolecules 
cannot pass through blood vessels and are thus concentrated) [70]. The same effect can be noticed if 
the tourniquet application exceeds one minute. Indeed, proteins and macromolecules can thus 
accumulate upstream the tourniquet and be detected at a higher rate than normal by this effect of 
concentration. Moreover, Cengiz et al. have shown in a recent study that erythrocyte deformability is 
still altered up to 180 seconds after tourniquet removal, and erythrocyte aggregation is increased up to 
30 seconds after tourniquet removal [71]. They also confirmed that tourniquet application induces 
leukocytes activation. 
Concerning the needle bore size, too thin needle can induce hemolysis, thus free hemoglobin and 
other protein concentrations increase in serum/plasma. It is not problematic when working with blood 
products obtained from whole blood donation because in case of large blood drawn volume, largest 
needles are used (16 to 19-gauge needles). In routine venipuncture, smaller blood volumes are drawn 
and patient comfort is of high importance, thus thinner needles are chosen (21 to 23-gauge needles). 
However, too thin needles (25-gauge needles) should be avoided since it can induce pre-analytical 
variability (hemolysis), leading to false interpretation of test results [72,73].  
3.3.2. Sample Container Type 
All containers have to be tested for a possible interference with analyses to be performed. Indeed, 
containers can salt out plastic components, which can be detected in analysis by mass spectrometry. 
The presence of polymers in an MS analysis induces effect of signal suppression: the high amount of 
ionized polymer saturates the detector, and the other sample minority components ions cannot be 
detected anymore. In 2004, Drake et al. have demonstrated the presence of polymers on mass spectra 
from extracts of saline solution incubated in different blood sample containers, from two different 
manufacturers [74]. 
Investigating serum/plasma proteomes, Hsieh et al. have shown that there was no significant 
difference between samples collected in glass red-top tubes and samples collected in serum separator 
tiger-top tubes [75]. However, comparing the nature of the anticoagulant used, they have found high 
significant differences in plasma protein profiles. Most common anticoagulants are EDTA, heparin and 
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sodium citrate. Their different action ways lead to these differences in proteome composition. 
Moreover, they are also known to interfere with subsequent analysis. EDTA is known to interfere in 
enzymatic activity assays, whereas heparin is not advised for some ELISA-based assay kit.  
3.3.3. Sample Processing and Handling 
First of all, the time between blood donation and preparation of the labile products is of high 
importance. Banks et al. have shown in 2005 that this duration induces differences in SELDI-TOF 
profiles of plasma collected with different anticoagulants and serum samples [76].  
A study of West-Nielson et al., based on principal component analysis (PCA) of MALDI-TOF 
spectra, reveals that there was no significant difference between spectra of serum from blood left to 
clot up to 24 h at 4 °C and from blood left to clot up to 4 h at 24 °C [77]. However, when blood is left 
to clot for longer times at 24 °C (8 h to 24 h), clearly changes appear in mass spectra, which was 
confirmed later [75]. In 2007, Timms et al. have shown that both transport time and temperature play a 
role on SELDI-TOF spectra profiles of sera [78]. 
Studying RBC microparticles, Rubin et al. have encountered some pre-analytical caveats. Indeed, 
our group has shown that sample processing temperature and vortexing duration affect microparticles 
counting [79]. Dealing with centrifugation force (1500 or 3000 × g) and duration (15 vs. 30 minutes), 
serum proteome profiles do not appear to be affected [75].  
Protein degradations, such as fragmentation by proteolysis, and protein modification, such as 
oxidation, have been described as storage lesions (see part 2). However, these alterations can be 
induced during sample manipulation, and cannot be differentiated from storage lesions. The addition of 
protease inhibitors to prevent handling-related proteolysis is thus of high importance. If protease 
inhibitors are omitted, it has been shown that low molecular weight compounds appear and accumulate 
during sample preparation [80]. It is necessary to prevent proteolytic cleavages because generated 
peptides could thus be mistaken for potential biomarker. Indeed, analyzing peptidome variations of 
pathological sera, Davis et al. have shown that modifications in low molecular weight compounds 
reveal disease-induced hemostatic dysregulation rather than direct protease activity of a given 
pathology [81]. Indirectly pathologically-induced peptidome variations are not specific enough to be 
considered as good biomarkers and have thus to be avoided by use of protease inhibitors, even if it is 
not known whether all protease activities are repressed.  
RBCs possess a set of enzymes responsible for antioxidant defense (catalase, superoxide dismutase, 
peroxiredoxins and glutathione peroxidase). However, these enzymes can be inactivated by excess of 
reactive oxygen species (ROS), and additional protein oxidation can thus occur during sample 
processing. In order to prevent this phenomenon, particularly prior to cystein oxidation assessment in 
stored RBC redox proteomic studies, cell-permeable cystein-specific reagents, such as iodoacetamide 
(IAA) or N-ethylmaleimide (NEM) alkylating agents, are commonly used [82,83]. 
3.3.4. Sample Storage 
Storage conditions are important to preserve quality of labile blood products and to ensure the 
efficiency of transfusion therapy. Thus, it is known that erythrocyte concentrates are preferentially 
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stored at 4 °C whereas platelet concentrates are stored at 22 °C to prevent cold activation of platelets. 
Finally, fresh frozen plasma is stored at −25 °C at least. 
Thus, whole blood storage cannot ensure optimal preservation of each blood components. In labile 
blood products aging field, samples are ECs, PCs or FFPs, and are stored according to blood banking 
legislation. In pathological-case biomarker research, samples are either serum or plasma, and are not 
subject to any storage legislation. Several studies aimed at investigating the reproducibility of analysis 
after storage at −20/−30 °C or −80 °C, and after freeze-thaw cycles [75,84,85]. It appears that storage 
at −20 °C instead of the recommended −80 °C storage does not induce loss of information. Samples 
stored at −20/−30 °C can thus be used for biomarker discovery [86].  
Some proteins have been shown to be highly temperature-sensitive: cryoproteins. Described for the 
first time in the 1930’s by Wintrobe  [87] as myeloma’s patient sera precipitating at cold temperature, 
cryoproteins are serum or plasma proteins having the property to precipitate below the  physiological 
temperature. Most of the time composed of immunoglobulins (mainly IgM) these precipitates are 
called cryoglobulins (CG), and are classified under three categories according to the universally 
adopted classification of Brouet [88]. Other proteins have this particularity to precipitate at low 
temperature, as cryofibrinogen (CF) (for instance, see the study on clinical cases of patients with either 
CF alone or combined CF plus CG [89]) and cold agglutinins. Proteomic techniques are well adapted 
to determine the protein composition of cryoprecipitates [90]. Cryoproteins are potential biomarkers, 
and pre-analytical precautions have to be taken for their investigation. Indeed, blood must be sampled 
in anticoagulant-free, 37 °C pre-heated container, handled and centrifuged at 37 °C, in order to prevent 
cryoprotein elimination by precipitation before analysis. 
Table 1. Main pre-analytical conditions to respect for proteomic analyses of labile blood 
products and blood samples in biomarker discovery field. 
 
Labile blood products Blood sample for pathological-
case biomarker research 
References 
ECs PCs FFP 
Sampling 
sample obtention 
donor position resting position [68] 
tourniquet application less than 30 seconds if possible, no more than 1 minute [69] 
needle bore size avoid too thin needle (21–23 gauge needles are preferred) [70,71] 
container type 
material approved plastic bags 
vacuette®-like blood collection 
tubes 
[72,73] 
anticoagulant content Citrate Phosphate Dextrose (CPD) depends on  analyses [73] 
processing 
and 
handling 
time between sampling and processing up to 24 h at +4 °C or up to 4 h at +24 °C [74,75] 
transport time and temperature controlled transport at +4 °C, must be as brief as possible [76] 
centrifugation prefer centrifugation at +4 °C, up to 3000 × g [73] 
use of protease inhibitors required to avoid proteolysis [78,79] 
use of antioxidant reagents needed in case of redox proteomic studies [80,81] 
storage 
temperature 
original sample +4 °C +22 °C −25 °C −20/−30 °C or −80 °C [73,82,83] 
proteinic extracts −20/−30 °C and −80 °C stored extracts are both suitable [84] 
freeze/thaw cycles better only once, but several cycles do not affect proteomic patterns [73,82,83] 
case of cryoproteins always work at 37 °C (pre-heated containers) [87] 
Int. J. Mol. Sci. 2010, 11             
 
 
4611 
4. Conclusions 
Pre-analytics is of very high importance for all kind of test, assay and discovery field, and more 
importantly in biomarker discovery field, due to the direct clinical implications. Uncontrolled  
pre-analytical parameters may lead to false interpretation of results. 
In clinical proteomics, reproducibility is indispensable and is straightly correlated with  
pre-analytical considerations. Standardization of sample harvesting, process, and storage has to be set 
up in order to minimize pre-analytical variations. Biomarker discovery is such a complicated field that 
there is no time to waste in wondering if an observed protein variation is due to different physiological 
states or simply to differences in sample handling or storage. Many small-scale standardized protocols 
exist in laboratories and lots of pre-analytical parameters have been investigated so far. Time is now 
about setting up worldwide-scale standardization of sample handling, process and storage.  
The human proteome organization (HUPO) has set up the plasma proteome project (HPPP), in 
order to perform a comprehensive analysis of plasma and serum protein constituents in people. A 
specimen collection and handling committee (SCHC) was created to evaluate pre-analytical variables 
that can potentially impact experiment results. In this purpose, Rai et al. have conducted in 2005 a 
proteomic study, comparing serum and plasma analyses, evaluating storage and handling conditions as 
well as the use of protease inhibitors [91]. They were thus able to present general recommendations 
helping researchers to set up more robust plasma proteome studies. This is an important step towards 
the establishment of standardized protocols for proteome studies, which is primordial in the biomarker 
discovery field.  
This kind of initiative is important for the transfusion medicine community and for the whole 
clinical medicine community as well. Reviews about importance of the pre-analytics in many fields are 
regularly published nowadays, which means that procedures standardization is a real  
contemporary thought. 
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